Pacira Pharmaceuticals Inc., of Parsippany, N.J., said net product sales of postsurgical pain product Exparel (bupivacaine liposome injectable suspension) were $34.4 million in the first quarter of 2014, compared to $10.4 million in the first quarter of 2013.